These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 16443220

  • 1. Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
    Gutiérrez-Berzal J, Castellano E, Martín-Encabo S, Gutiérrez-Cianca N, Hernández JM, Santos E, Guerrero C.
    Exp Cell Res; 2006 Apr 01; 312(6):938-48. PubMed ID: 16443220
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
    Gutiérrez-Castellanos S, Cruz M, Rabelo L, Godínez R, Reyes-Maldonado E, Riebeling-Navarro C.
    Eur J Haematol; 2004 Apr 01; 72(4):231-8. PubMed ID: 15089759
    [Abstract] [Full Text] [Related]

  • 5. Tyrosine phosphorylation of murine Crkl.
    de Jong R, Haataja L, Voncken JW, Heisterkamp N, Groffen J.
    Oncogene; 1995 Oct 19; 11(8):1469-74. PubMed ID: 7478571
    [Abstract] [Full Text] [Related]

  • 6. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ, Albitar M.
    Leuk Res; 2008 Apr 19; 32(4):643-9. PubMed ID: 17900686
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Molecular and structural characterization of the SH3 domain of AHI-1 in regulation of cellular resistance of BCR-ABL(+) chronic myeloid leukemia cells to tyrosine kinase inhibitors.
    Liu X, Chen M, Lobo P, An J, Grace Cheng SW, Moradian A, Morin GB, Van Petegem F, Jiang X.
    Proteomics; 2012 Jul 19; 12(13):2094-106. PubMed ID: 22623184
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells.
    Tari AM, Arlinghaus R, Lopez-Berestein G.
    Biochem Biophys Res Commun; 1997 Jun 18; 235(2):383-8. PubMed ID: 9199202
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.
    Sekine Y, Ikeda O, Mizushima A, Ueno Y, Muromoto R, Yoshimura A, Kanakura Y, Oritani K, Matsuda T.
    Oncogene; 2012 Oct 04; 31(40):4384-96. PubMed ID: 22231445
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.